No Data
No Data
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Promising Phase 2a Trial Results and Upcoming Catalysts Drive Buy Rating for SELLAS Life Sciences Group
SELLAS Succeeds in Mid-stage Study for Myeloid Leukemia Treatment
Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up
Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009
Express News | Sellas Life Sciences Group Inc: Trial Continues With Full Data and FDA Regulatory Path Feedback Expected in 1H 2025